ScholarDeck

GuidelineNeurologia · 2026

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

R Sánchez-Valle, D Alcolea, G Amer Ferrer … Spanish Society of Neurology’s Behavioural Neurology, Dementia Study Group working group for the appropriate use of anti-amyloid monoclonal antibody treatment

Read paper

NeurologyGuideline

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

R Sánchez-Valle et al. · Neurologia · 2026

Background

Two anti-amyloid monoclonal antibodies (mAb) have recently been approved by the European Commission for the treatment of Alzheimer disease (AD).

Methods

Noted concerns about equity of access and implementation into current care, particularly if insufficient resources are allocated to this implementation.

More results

DEVELOPMENT: Fifty-seven members of the study group participated in the consensus process (January-September 2025), which includes recommendations on criteria for selecting candidates, adverse reactions, monitoring, criteria for suspension of treatment, shared physician-patient decision-making, and requirements of prescribing centres.

More results

This document will require updates in line with new knowledge and/or approval of new drugs in this class.

Post

Appropriate use recommendations of the Spanish Society of Neurology's Behavioural Neurology and Dementia Study Group on anti-amyloid antibodies in the treatment of Alzheimer disease.

Related papers